Affordable Access

Access to the full text

When Therapeutic IgA Antibodies Might Come of Age

Authors
  • Sterlin, Delphine
  • Gorochov, Guy
Type
Published Article
Journal
Pharmacology
Publisher
S. Karger AG
Publication Date
Sep 18, 2020
Volume
106
Issue
1-2
Pages
9–19
Identifiers
DOI: 10.1159/000510251
PMID: 32950975
Source
Karger
Keywords
License
Green
External links

Abstract

Background: Extensive efforts have been made in optimizing monoclonal immunoglobulin (Ig)G antibodies for use in clinical practice. Accumulating evidence suggests that IgA or anti-FcαRI could also represent an exciting avenue toward novel therapeutic strategies. Summary: Here, we underline that IgA is more effective in recruiting neutrophils for tumor cell killing and is potently active against several pathogens, including rotavirus, poliovirus, influenza virus, and SARS-CoV-2. IgA could also be used to modulate excessive immune responses in inflammatory diseases. Furthermore, secretory IgA is emerging as a major regulator of gut microbiota, which impacts intestinal homeostasis and global health as well. As such, IgA could be used to promote a healthy microbiota in a therapeutic setting. Key messages: IgA combines multifaceted functions that can be desirable for immunotherapy.

Report this publication

Statistics

Seen <100 times